Bearish for GSK the expanded label might have added some 10-15M eligible patients but more importantly enabled them to stay ahead of the competition wrt contracting
“Also, ACIP did not make any recommendation on whether—or when—people should receive a second RSV vaccination. “
The first patients eligible for revaccination won’t happen until the 25-26 season so there was no urgency here. I’m still assuming annual for MRNA amd biennial for GSK/PFE
Market Data 
Markets 
AI
